High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Statins reduce the incidence of strokes among patients at increased risk for cardiovascular disease; whether they reduce the risk of stroke after a recent stroke or transient ischemic attack (TIA) remains to be established. METHODS: We randomly assigned 4731 patients who had had a stroke or TIA within one to six months before study entry, had low-density lipoprotein (LDL) cholesterol levels of 100 to 190 mg per deciliter (2.6 to 4.9 mmol per liter), and had no known coronary heart disease to double-blind treatment with 80 mg of atorvastatin per day or placebo. The primary end point was a first nonfatal or fatal stroke. RESULTS: The mean LDL cholesterol level during the trial was 73 mg per deciliter (1.9 mmol per liter) among patients receiving atorvastatin and 129 mg per deciliter (3.3 mmol per liter) among patients receiving placebo. During a median follow-up of 4.9 years, 265 patients (11.2 percent) receiving atorvastatin and 311 patients (13.1 percent) receiving placebo had a fatal or nonfatal stroke (5-year absolute reduction in risk, 2.2 percent; adjusted hazard ratio, 0.84; 95 percent confidence interval, 0.71 to 0.99; P=0.03; unadjusted P=0.05). The atorvastatin group had 218 ischemic strokes and 55 hemorrhagic strokes, whereas the placebo group had 274 ischemic strokes and 33 hemorrhagic strokes. The five-year absolute reduction in the risk of major cardiovascular events was 3.5 percent (hazard ratio, 0.80; 95 percent confidence interval, 0.69 to 0.92; P=0.002). The overall mortality rate was similar, with 216 deaths in the atorvastatin group and 211 deaths in the placebo group (P=0.98), as were the rates of serious adverse events. Elevated liver enzyme values were more common in patients taking atorvastatin. CONCLUSIONS: In patients with recent stroke or TIA and without known coronary heart disease, 80 mg of atorvastatin per day reduced the overall incidence of strokes and of cardiovascular events, despite a small increase in the incidence of hemorrhagic stroke. (ClinicalTrials.gov number, NCT00147602 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the recently published Lipitor's Effect in Alzheimer's Dementia (LEADe) trial, which included 640 randomized patients with mild Alzheimer disease, intensive lipid lowering by the addition of atorvastatin (80 mg) to donepezil did not improve cognitive function over a 72-week period.464”
In the citing paper
“Data from RCTs and meta-analyses indicate that routine early use of high-intensity statin therapy is associated with rapid and sustained clinical benefits [438-442].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [438]
In the citing paper
“Following stroke or TIA, 34 patients are at risk not only of recurrent cerebrovascular events but also of other major CV events including MI.”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [34]
In the citing paper
“Secondary prevention therapy with statins reduces the risk of recurrent stroke (by 12%), MI and vascular death.422,428”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [428]
In the citing paper
“Many reports have also indicated that there is no clear relationship between the TG level and cerebrovascular disease856, 862, 863).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [862]
Citations
Cites
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Cerebral Vascular Accidents in Patients over the Age of 60: II. Prognosis
Rankin, J. (1957) · Scottish Medical Journal · doi:10.1177/003693305700200504 · Cited by 2,506
Sacco, R. L., Adams, R., Albers, G., Alberts, M. J., Benavente, O., Furie, K., Goldstein, L. B., Gorelick, P., Halperin, J., Harbaugh, R., et al. (2006) · Stroke · doi:10.1161/01.str.0000199147.30016.74 · Cited by 1,873
Iso, H., Jacobs, D. R., Wentworth, D., Neaton, J. D., Cohen, J. D., & for the MRFIT Research Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198904063201405 · Cited by 1,133
Amarenco, P., Labreuche, J., Lavallée, P., & Touboul, P.-J. (2004) · Stroke · doi:10.1161/01.str.0000147965.52712.fa · Cited by 746
Research works printed but not linked: 1
- Waters DD, 2005, Circulation, 112, 2020
Cited by
Items 401–500 of 1,005
Riemsma, R., Corro Ramos, I., Birnie, R., Büyükkaramikli, N., Armstrong, N., Ryder, S., Duffy, S., Worthy, G., Al, M., Severens, J., et al. (2016) · Health Technology Assessment · doi:10.3310/hta20170 · Cited by 73
Determinants and Outcomes of Asymptomatic Intracranial Atherosclerotic Stenosis
Gutierrez, J., Khasiyev, F., Liu, M., DeRosa, J. T., Tom, S. E., Rundek, T., Cheung, K., Wright, C. B., Sacco, R. L., & Elkind, M. S. V. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.05.041 · Cited by 72
Suzuki, K., Izumi, M., Sakamoto, T., & Hayashi, M. (2010) · Cerebrovascular Diseases · doi:10.1159/000321506 · Cited by 72
Derdeyn, C. P., & Chimowitz, M. I. (2007) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2007.05.001 · Cited by 75
Cerebral Microbleeds: Detection, Mechanisms and Clinical Challenges
Charidimou, A., & Werring, D. J. (2011) · Future Neurology · doi:10.2217/fnl.11.42 · Cited by 82
High-dose statin therapy and risk of intracerebral hemorrhage: a meta-analysis
Pandit, A. K., Kumar, P., Kumar, A., Chakravarty, K., Misra, S., & Prasad, K. (2015) · Acta Neurologica Scandinavica · doi:10.1111/ane.12540 · Cited by 72
Masana, L., Girona, J., Ibarretxe, D., Rodríguez‐Calvo, R., Rosales, R., Vallvé, J.-C., Rodríguez-Borjabad, C., Guardiola, M., Rodríguez, M. M., Guaita‐Esteruelas, S., et al. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.12.018 · Cited by 75
Statins and Risk of Intracerebral Hemorrhage in Individuals With a History of Stroke
Ribe, A. R., Vestergaard, C. H., Vestergaard, M., Pedersen, H. S., Prior, A., Lietzen, L. W., Brynningsen, P. K., & Fenger‐Grøn, M. (2020) · Stroke · doi:10.1161/strokeaha.119.027301 · Cited by 71
Li, J., Pan, Y., Xu, J., Li, S., Wang, M., Quan, K., Meng, X., Li, H., Lin, J., Wang, Y., et al. (2021) · Stroke · doi:10.1161/strokeaha.120.033152 · Cited by 74
Lipid profile, statin use, and outcome after intravenous thrombolysis for acute ischaemic stroke
Uyttenboogaart, M., Koch, M. W., Koopman, K., Vroomen, P. C. A. J., Luijckx, G. J., & Keyser, J. D. (2008) · Journal of Neurology · doi:10.1007/s00415-008-0797-7 · Cited by 79
“sociation of low cholesterol levels, statin use and increased risk of haemorrhagic stroke [3, 14, 24], and this observation was corroborated in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study [7].”
ResultCortical superficial siderosis predicts early recurrent lobar hemorrhage
Roongpiboonsopit, D., Charidimou, A., William, C. M., Lauer, A., Falcone, G. J., Martínez‐Ramírez, S., Biffi, A., Ayres, A. M., Vashkevich, A., Awosika, O. O., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003281 · Cited by 81
The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): Design and baseline characteristics
Jones, R. W., Kivipelto, M., Feldman, H., Sparks, L. D., Doody, R. S., Waters, D. D., Hey‐Hadavi, J., Breazna, A., Schindler, R. J., Ramos, H., et al. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.02.001 · Cited by 74
Zhang, L., Zhang, Z. G., Liu, X., Hozeska‐Solgot, A., & Chopp, M. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.150748 · Cited by 74
Khan, S. U., Khan, M. U., Valavoor, S., Khan, M. S., Okunrintemi, V., Mamas, M. A., Leucker, T. M., Blaha, M. J., & Michos, E. D. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487319871733 · Cited by 67
Mok, C. C., Wong, C. K., To, C. H., Lai, J. P. S., & Lam, C. S. (2011) · Arthritis Care & Research · doi:10.1002/acr.20440 · Cited by 71
Inflammation markers and prediction of post-stroke vascular disease recurrence: The MITICO study
Castillo, J., Álvarez‐Sabín, J., Martínez‐Vila, E., Montaner, J., Sobrino, T., Vivancos, J., & on behalf of the MÍTICO Study Investigators* (2009) · Journal of Neurology · doi:10.1007/s00415-009-0058-4 · Cited by 81
II. Cerebral Infarction/Transient Ischemic Attack (TIA)
Shinohara, Y., Yanagihara, T., Abe, K., Yoshimine, T., Fujinaka, T., Chuma, T., Ochi, F., Nagayama, M., Ogawa, A., Suzuki, N., et al. (2011) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2011.05.004 · Cited by 74
Risk Factor Management to Prevent First Stroke
Rundek, T., & Sacco, R. L. (2008) · Neurologic Clinics · doi:10.1016/j.ncl.2008.09.001 · Cited by 83
Risk Factor Profile and Management of Cerebrovascular Patients in the REACH Registry
Röther, J., Alberts, M. J., Touzé, E., Mas, J., Hill, M. D., Michel, P., Bhatt, D. L., Aichner, F., Goto, S., Matsumoto, M., et al. (2008) · Cerebrovascular Diseases · doi:10.1159/000120687 · Cited by 74
Kim, B. J., Lee, S., Ryu, W., Kang, B. S., Kim, C. K., & Yoon, B. (2009) · Stroke · doi:10.1161/strokeaha.108.539643 · Cited by 69
Stroke, obesity and gender: A review of the literature
Katsiki, N., Ntaios, G., & Vemmos, K. N. (2011) · Maturitas · doi:10.1016/j.maturitas.2011.04.010 · Cited by 82
Itoh, H., Komuro, I., Takeuchi, M., Akasaka, T., Daida, H., Egashira, Y., Fujita, H., Higaki, J., Hirata, K., Ishibashi, S., et al. (2018) · Diabetes Care · doi:10.2337/dc17-2224 · Cited by 72
Leichtle, S. W., Mouawad, N. J., Welch, K. B., Lampman, R. M., Whitehouse, W. M., & Heidenreich, M. (2012) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2012.01.005 · Cited by 68
Statin pretreatment is associated with better outcomes in large artery atherosclerotic stroke
Tsivgoulis, G. K., Katsanos, A. H., Sharma, V. K., Krogias, C., Mikulík, R., Vadikolias, Κ., Mijajlovic, M. D., Safouris, A., Zompola, C., Faissner, S., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002493 · Cited by 73
Management of intracerebral hemorrhage
Thabet, A. M., Kottapally, M., & Hemphill, J. C. (2017) · Handbook of clinical neurology · doi:10.1016/b978-0-444-63600-3.00011-8 · Cited by 74
“…lipoproteins and triglycerides as well as high-dose statin therapy have been thought to be risk factors for the occurrence of primary ICH (Amarenco et al., 2006; Sturgeon et al., 2007), a recent retrospective cohort study of 3481 patients with ICH found that cessation of statin use was…”
BackgroundBrott, T. G., Halperin, J. L., Abbara, S., Bacharach, J. M., Barr, J. D., Bush, R. L., Cates, C. U., Creager, M. A., Fowler, S. A., Friday, G. H., et al. (2011) · Journal of NeuroInterventional Surgery · doi:10.1136/jnis.2011.004762 · Cited by 73
Scrutinio, D., Lanzillo, B., Guida, P., Passantino, A., Spaccavento, S., & Battista, P. (2019) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2019.11.012 · Cited by 76
How low is safe? The frontier of very low (<30 mg/dL) LDL cholesterol
Karagiannis, A. D., Mehta, A., Dhindsa, D. S., Virani, S. S., Orringer, C. E., Blumenthal, R. S., Stone, N. J., & Sperling, L. S. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1080 · Cited by 81
Wardlaw, J. M., Chabriat, H., de Leeuw, F., Debette, S., Dichgans, M., Doubal, F., Jokinen, H., Katsanos, A. H., Ornello, R., Pantoni, L., et al. (2024) · European Stroke Journal · doi:10.1177/23969873231219416 · Cited by 80
Best evidence for medical therapy for carotid artery stenosis
Constantinou, J., Jayia, P., & Hamilton, G. (2013) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2013.06.085 · Cited by 70
Young, L. H., Viscoli, C. M., Curtis, J. P., Inzucchi, S. E., Schwartz, G. G., Lovejoy, A. M., Furie, K. L., Gorman, M. J., Conwit, R., Abbott, J. D., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.024863 · Cited by 66
Khan, S. U., Talluri, S., Riaz, H., Rahman, H., Nasir, F., Bin Riaz, I., Sattur, S., Ahmed, H., Kaluski, E., & Krasuski, R. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318766612 · Cited by 61
Alberton, M., Wu, P., Druyts, E., Briel, M., & Mills, E. J. (2011) · QJM · doi:10.1093/qjmed/hcr158 · Cited by 73
Carbone, F., Teixeira, P. C., Braunersreuther, V., Mach, F., Vuilleumier, N., & Montecucco, F. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5778 · Cited by 69
Coronary Artery Disease and Risk of Major Vascular Events After Cerebral Infarction
Amarenco, P., Lavallée, P. C., Labreuche, J., Ducrocq, G., Juliard, J., Feldman, L. J., Cabrejo, L., Meseguer, E., Guidoux, C., Adraï, V., et al. (2013) · Stroke · doi:10.1161/strokeaha.111.000142 · Cited by 69
Atorvastatin enhances angiogenesis to reduce subdural hematoma in a rat model
Wang, D., Li, T., Wei, H., Wang, Y., Yang, G., Tian, Y., Zhao, Z., Wang, L., Yu, S., Zhang, Y., et al. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.01.017 · Cited by 66
Wang, Y., Chen, Q., Tan, Q., Feng, Z., He, Z., Tang, J., Feng, H., Zhu, G., & Chen, Z. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.10.021 · Cited by 75
“Statin was related with reducing the overall incidence of stroke (Amarenco et al., 2006; McKinney and Kostis, 2012), and promoting outcome recovery after ischemic stroke (Hong and Lee, 2015).”
Epidemiology and Primary Prevention of Stroke
Furie, K. L. (2020) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000831 · Cited by 77
Miida, T., Takahashi, A., & Ikeuchi, T. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.09.003 · Cited by 72
Paciaroni, M., Hennerici, M. G., Agnelli, G., & Bogousslavsky, J. (2007) · Cerebrovascular Diseases · doi:10.1159/000104474 · Cited by 72
Sun, H., & Singh, N. (2009) · Clinical Infectious Diseases · doi:10.1086/597039 · Cited by 65
Guía de la ESC/EAS sobre el manejo de las dislipemias
Reiner, Ž., Catapano, A. L., Backer, G. D., Graham, I. M., Taskinen, M., Wiklund, O., Agewall, S., Alegría, E., Chapman, M. J., Durrington, P. N., et al. (2011) · Revista Española de Cardiología · doi:10.1016/j.recesp.2011.09.014 · Cited by 80
Risk Factors for Stroke in Patients With Sepsis and Bloodstream Infections
Shao, I. Y., Elkind, M. S. V., & Boehme, A. K. (2019) · Stroke · doi:10.1161/strokeaha.118.023443 · Cited by 72
Awareness, Treatment, and Control of Vascular Risk Factors among Stroke Survivors
Brenner, D. A., Zweifler, R. M., Gomez, C. R., D, B. M. K. M., Levine, D. A., Howard, G., Coull, B. M., & Howard, V. J. (2010) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2009.07.001 · Cited by 65
Lipoprotein-Associated Phospholipase A2 and Risk of Stroke
Gorelick, P. B. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.04.017 · Cited by 73
Patterns of complementary and alternative medicine use among United States stroke survivors
Shah, S., Engelhardt, R., & Ovbiagele, B. I. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2008.04.014 · Cited by 66
“John's wort showed that it significantly increased LDL cholesterol in patients taking atorvastatin [22], the latter of which was recently shown to reduce secondary stroke risk, and will likely now be widely prescribed for stroke patients [23].”
BackgroundGuidelines for acute ischemic stroke treatment: part II: stroke treatment
Martins, S. C. O., de Freitas, G. R., Pontes‐Neto, O. M., Pieri, A., Moro, C. H. C., de Jesus, P. A. P., Longo, A. L., Evaristo, E. F., de Carvalho, J. J. F., Fernandes, J. G., et al. (2012) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x2012001100012 · Cited by 69
Impact of HMG-CoA reductase inhibition on brain pathology
Zipp, F., Waiczies, S., Aktaş, O., Neuhaus, O., Hemmer, B., Schraven, B., Nitsch, R., & Hartung, H. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.05.001 · Cited by 71
Cochrane review on ‘Statins for the treatment of dementia’
McGuinness, B., O’Hare, J., Craig, D., Bullock, R. A., Malouf, R. S., & Passmore, P. (2012) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.3797 · Cited by 64
Food and Western Disease Health and Nutrition from an Evolutionary Perspective
Lindeberg, S. (2009) · Cited by 64
Intracranial Atherosclerosis Treatment
Flusty, B., de Havenon, A., Prabhakaran, S., Liebeskind, D. S., & Yaghi, S. R. (2020) · Stroke · doi:10.1161/strokeaha.119.028528 · Cited by 67
“99]).(11) A trend toward secondary stroke prevention was also seen in patients whose index stroke was attributed to large artery atherosclerosis (HR, 0.”
BackgroundPuato, M., Faggin, E., Rattazzi, M., Zambon, A., Cipollone, F., Grego, F., Ganassin, L., Plebani, M., Mezzetti, A., & Pauletto, P. (2010) · Stroke · doi:10.1161/strokeaha.110.580811 · Cited by 68
Kinlay, S., Schwartz, G. G., OLSSON, A. G., Rifai, N., Szarek, M. J., Waters, D. D., Libby, P., & Ganz, P. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.151787 · Cited by 64
Saposnik, G., Goodman, S. G., Leiter, L. A., Yan, R. T., FITCHETT, D. H., Bayer, N., Casanova, A., Langer, A., Yan, A. T.-K., & Guidelines-Oriented Approach to Lipid-Lowering (GOALL) Registries Investigators (2009) · Stroke · doi:10.1161/strokeaha.108.533018 · Cited by 73
Makris, G. C., Lavida, A., Nicolaides, A. N., & Geroulakos, G. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.04.032 · Cited by 69
“[1 5] 2 0 2 2 2 2 2 0 – – – – 12 /1 6”
Cholesterol, diabetes and major cardiovascular diseases in the Asia-Pacific region
Asia Pacific Cohort Studies Collaboration (2007) · Diabetologia · doi:10.1007/s00125-007-0801-2 · Cited by 69
Yaghi, S. R., Furie, K. L., Viscoli, C. M., Kamel, H., Gorman, M., Dearborn, J. L., Young, L. H., Inzucchi, S. E., Lovejoy, A. M., Kasner, S. E., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.030458 · Cited by 73
2015 Korean Guidelines for Management of Dyslipidemia
Committee for Guidelines for Management of Dyslipidemia (2015) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2015.4.1.61 · Cited by 71
Statin Treatment in Patients With Intracerebral Hemorrhage
Endres, M., Nolte, C. H., & Scheitz, J. F. (2017) · Stroke · doi:10.1161/strokeaha.117.019322 · Cited by 70
Improving journal club presentations, or, I can present that paper in under 10 minutes
Schwartz, M. D., Dowell, D., Aperi, J., & Kalet, A. L. (2007) · BMJ Evidence-Based Medicine · doi:10.1136/ebm.12.3.66-a · Cited by 63
Dynamic Temporal Change of Cerebral Microbleeds: Long-Term Follow-Up MRI Study
Lee, S., Lee, S., Kim, B. J., Park, H.-K., Kim, C.-K., Jung, K., & Roh, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025930 · Cited by 65
Lipids and carotid plaque in the Northern Manhattan Study (NOMAS)
Gardener, H. E., Della‐Morte, D., Elkind, M. S. V., Sacco, R. L., & Rundek, T. (2009) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-9-55 · Cited by 67
Xian, Y., O'Brien, E. C., Fonarow, G. C., Olson, D. M., Schwamm, L. H., Hannah, D., Lindholm, B., Maisch, L., Lytle, B. L., Greiner, M. A., et al. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.04.008 · Cited by 68
Nießen, J., Jedlitschky, G., Grube, M., Bien, S., Schwertz, H., Ohtsuki, S., Kawakami, H., Kamiie, J., Oswald, S., Starke, K., et al. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.024570 · Cited by 62
“Our findings are of interest with respect to some observations in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial (Amarenco et al., 2006).”
BackgroundResultPeng, B., Ni, J., Anderson, C. S., Zhu, Y., Wang, Y., Pu, C., Wu, J., Wang, J. M., Zhou, L., Yao, M., et al. (2014) · Stroke · doi:10.1161/strokeaha.113.001424 · Cited by 62
Wang, S., Cai, R., Yuan, Y., Varghese, Z., Moorhead, J. F., & Ruan, X. Z. (2017) · Scientific Reports · doi:10.1038/srep39982 · Cited by 79
Cerebral amyloid angiopathy: diagnosis and potential therapies
Weber, S. A., Patel, R. K., & Lutsep, H. L. (2018) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2018.1480938 · Cited by 72
Recent Advances in Primary and Secondary Prevention of Atherosclerotic Stroke
Tsivgoulis, G. K., Safouris, A., Kim, D., & Alexandrov, A. V. (2018) · Journal of Stroke · doi:10.5853/jos.2018.00773 · Cited by 74
High Cholesterol Levels Are Associated with Improved Long-term Survival after Acute Ischemic Stroke
Markaki, I., Nilsson, U., Kostulas, K., & Sjöstrand, C. (2013) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2013.08.009 · Cited by 64
Multifunctional Actions of Approved and Candidate Stroke Drugs
Minnerup, J., & Schäbitz, W. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.10.032 · Cited by 62
Common cardiovascular medications in cancer therapeutics
Vaklavas, C., Chatzizisis, Y. S., & Tsimberidou, A. M. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.009 · Cited by 68
Differentiating ischemic stroke subtypes: Risk factors and secondary prevention
Kirshner, H. S. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2008.12.012 · Cited by 73
Perera, R., McFadden, E. C., McLellan, J., Lung, T. W.-C., Clarke, P., Pérez, T., Fanshawe, T. R., Dalton, A. R., Farmer, A. A., Glasziou, P., et al. (2015) · Health Technology Assessment · doi:10.3310/hta191000 · Cited by 67
Pagidipati, N. J., Návar, A. M., Pieper, K. S., Green, J. B., Bethel, M. A., Armstrong, P. W., Josse, R. G., McGuire, D. K., Lokhnygina, Y. V., Cornel, J. H., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.027252 · Cited by 65
Otte, C., Zhao, S., & Whooley, M. A. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07038 · Cited by 66
Lipid lowering therapy in cardiovascular disease: From myth to molecular reality
Mourikis, P., Zako, S., Dannenberg, L., Nia, A. M., Heinen, Y., Busch, L., Richter, H., Hohlfeld, T., Zeus, T., Kelm, M., et al. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107592 · Cited by 62
Neuroprotection during Thrombectomy for Acute Ischemic Stroke: A Review of Future Therapies
Dammavalam, V. M., Lin, S. Y., Nessa, S., Daksla, N., Stefanowski, K., Costa, A., & Bergese, S. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020891 · Cited by 64
“Similarly, in a randomized controlled trial of patients treated with a high-intensity statin daily, there was a 16% relative risk reduction of fatal and nonfatal strokes [13].”
BackgroundPathak, N. N., Balaganur, V., Lingaraju, M. C., Kant, V., Latief, N., More, A. S., Kumar, D., Kumar, D., & Tandan, S. K. (2014) · Neurochemistry International · doi:10.1016/j.neuint.2014.01.014 · Cited by 69
Bonifacio, A., Mullen, P. J., Mityko, I. S., Navegantes, L. C. C., Bouitbir, J., & Krähenbühl, S. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1378-4 · Cited by 63
Association of Prestroke Statin Use and Lipid Levels With Outcome of Intracerebral Hemorrhage
Mustanoja, S. M., Strbian, D., Jukka Putaala, A., Meretoja, A., Curtze, S., Haapaniemi, E., Sairanen, T., Hietikko, R., Sirén, J., Kaste, M., et al. (2013) · Stroke · doi:10.1161/strokeaha.113.001829 · Cited by 61
Diverse Effects of Statins on Angiogenesis: New Therapeutic Avenues
Elewa, H. F., El‐Remessy, A. B., Somanath, P. R., & Fagan, S. C. (2010) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.2.169 · Cited by 71
Brown, W. V. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328319baba · Cited by 61
White, C. J. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.04.069 · Cited by 63
Hsue, P. Y., Bittner, V., Betteridge, J. D., Fayyad, R. S., Laskey, R. E., WENGER, N. K., & Waters, D. D. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.11.026 · Cited by 59
Critical Care Management of Intracerebral Hemorrhage
Chan, S. L., & Hemphill, J. C. (2014) · Critical Care Clinics · doi:10.1016/j.ccc.2014.06.003 · Cited by 62
Cholesterol Lowering and Prevention of Stroke: An Overview
Hackam, D. G., & Hegele, R. A. (2019) · Stroke · doi:10.1161/strokeaha.118.023167 · Cited by 72
Fellström, B., Holdaas, H., Jardine, A. G., Rose, H., Schmieder, R. E., Wilpshaar, W., & Zannad, F. M. (2007) · Kidney & Blood Pressure Research · doi:10.1159/000106803 · Cited by 60
Effect of Pretreatment With Statins on Ischemic Stroke Outcomes
Reeves, M. J., Gargano, J. W., Luo, Z., Mullard, A. J., Jacobs, B. S., & Majid, A. (2008) · Stroke · doi:10.1161/strokeaha.107.501700 · Cited by 73
Statin Intolerance: Reconciling Clinical Trials and Clinical Experience
Newman, C. B., & Tobert, J. A. (2015) · JAMA · doi:10.1001/jama.2015.1335 · Cited by 63
Neurological deterioration in small vessel disease may be associated with increase of infarct volume
Terasawa, Y., Iguchi, Y., Kimura, K., Kobayashi, K., Aoki, J., Matsumoto, N., Shibazaki, K., Inoue, T., & Kaji, R. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.12.014 · Cited by 58
“Recent studies have shown that hypercholesterolemia causes focal activation of arterial endothelium and induces arterial atherosclerosis [20], and that high-dose statin therapy after stroke or transient ischemic attack reduced the incidence of stroke and of cardiovascular events [21].”
BackgroundStatins and Intracerebral Hemorrhage: A Retrospective Cohort Study
Hackam, D. G., Austin, P. C., Huang, A., Juurlink, D. N., Mamdani, M., Paterson, J. M., Hachinski, V., Li, P., & Kapral, M. K. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.228 · Cited by 65
Elkind, M. S. V., Sacco, R. L., MacArthur, R. B., Peerschke, E. I. B., Neils, G., Andrews, H., Stillman, J. I., Corporan, T. E., Leifer, D., Liu, R., et al. (2009) · Cerebrovascular Diseases · doi:10.1159/000228709 · Cited by 59
Irewall, A.-L., Ögren, J., Bergström, L., Laurell, K., Söderström, L., & Mooe, T. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139997 · Cited by 62
Amarenco, P., Kim, J. S., Labreuche, J., Charles, H., Giroud, M., Lee, B., Mahagne, M., Nighoghossian, N., Steg, P. G., Vicaut, É., et al. (2020) · Stroke · doi:10.1161/strokeaha.119.028718 · Cited by 71
“Centre Hospitalier de Montbelliard (3): Stantescu (PI), Marc Bataillard.”
BackgroundInfluentialFunciones de riesgo en la prevención primaria de las enfermedades cardiovasculares
Grau, M., & Marrugat, J. (2008) · Revista Española de Cardiología · doi:10.1157/13117732 · Cited by 78
Elkind, M. S. V., Sacco, R. L., MacArthur, R. B., Fink, D. J., Peerschke, E. I. B., Andrews, H., Neils, G., Stillman, J., Corporan, T. E., Leifer, D., et al. (2008) · International Journal of Stroke · doi:10.1111/j.1747-4949.2008.00200.x · Cited by 60
Shen, J. F., Huang, K., Zhu, Y., Pan, J.-W., Jiang, H., Weng, Y., & Zhan, R. (2016) · Journal of neurosurgery · doi:10.3171/2016.5.jns152900 · Cited by 58
Racial differences in recurrent ischemic stroke risk and recurrent stroke case fatality
Albright, K. C., Huang, L., Blackburn, J. L., Howard, G., Mullen, M. T., Bittner, V., Muntner, P., & Howard, V. J. (2018) · Neurology · doi:10.1212/wnl.0000000000006467 · Cited by 60
“PROGRESS was published, allowing for dissemination of results, through the year that the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial was published (publication date August 10, 2006).(25) SPARCLwas a randomized clinical trial that demonstrated the efficacy of a statin (atorvastatin) i…”
MethodValenti, R., Pantoni, L., & Markus, H. S. (2014) · BMC Medicine · doi:10.1186/s12916-014-0160-z · Cited by 51
Atherosclerosis As a Systemic Disease
Lahoz, C., & Mostaza, J. M. (2007) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(07)60131-5 · Cited by 84
Metadata
- Authors
- The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators
- Affiliations
- Université Paris Diderot (FR)
- Corresponding author
- The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-08-10
- Volume
- 355
- Issue
- 6
- Pages
- 549-559
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1546258268
- Cited by
- 2,887
- References
- 21
- Citations by year
- 2026: 86 · 2025: 96 · 2024: 119 · 2023: 112 · 2022: 135 · 2021: 134 · 2020: 139 · 2019: 140 · 2018: 129 · 2017: 132 · 2016: 139 · 2015: 125 · 2014: 142 · 2013: 160 · 2012: 149
- FWCI
- 200.93
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Eisai
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cerebrovascular and Carotid Artery Diseases
- Keywords
- atorvastatin, high-intensity statin therapy, stroke, transient ischemic attack, secondary stroke prevention, LDL cholesterol lowering, hemorrhagic stroke, ischemic stroke, cardiovascular events, elevated liver enzymes, lipid-lowering therapy, mortality, serious adverse events
- MeSH terms
- Atorvastatin, Adult, Cardiovascular Diseases, Cerebral Hemorrhage, Cerebral Infarction, Ischemic Attack, Transient, Drug Therapy, Combination, Female, Heptanoic Acids, Humans, Cholesterol, LDL, Male, Pyrroles, Risk, Proportional Hazards Models, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.